ReviewModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019
The utilization of cytologic and small biopsy samples for ancillary molecular testing.
Review in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Sample adequacy in bronchoscopic ROSE: comparison between laboratory specialist and pathologist.Pathology oncology research : POR · 2026Article
- Validation of ancillary procedures on formalin liquid fixed aspiration cytologic samples: from minimum to maximum.American journal of clinical pathology · 2025Article
- Morphologic and molecular diagnostic criteria of malignancies in biliary strictures.Histology and histopathology · 2025Review
- Article
- Next step of molecular pathology: next-generation sequencing in cytology.Journal of pathology and translational medicine · 2024Review
- Precision Medicine in Cytopathology.Surgical pathology clinics · 2024Review
- Rapid On-Site Evaluation Performed by an Interventional Pulmonologist: A Single-Center Experience.Journal of personalized medicine · 2024Article
- Immunocytochemistry on frozen-embedded cell block for the diagnosis of hematolymphoid cytology specimen: a straightforward alternative to the conventional cell block.Journal of hematopathology · 2024Article
- DNA Extracted from Cytologic Slides Is a Valuable Source for PCR-Based Molecular Tests.Acta cytologica · 2023Article
- The state of the art for artificial intelligence in lung digital pathology.The Journal of pathology · 2022Review
- Suitability of transbronchial needle aspiration for genotyping peripheral pulmonary tumors.Frontiers in medicine · 2022Article
- Tissue management in precision medicine: What the pathologist needs to know in the molecular era.Frontiers in molecular biosciences · 2022Review
- Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer.Frontiers in medicine · 2021Review
- The role of EBUS-TBNA in lung cancer restaging and mutation analysis.Mediastinum (Hong Kong, China) · 2020Review
- Molecular testing of cytology specimens: overview of assay selection with focus on lung, salivary gland, and thyroid testing.Journal of the American Society of CytopathologyReview
- Cytopathology 2.0: How Artificial Intelligence Is Redefining the Future of Cytopathology.Journal of cytologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has recently been an increased emphasis on the utilization of cytologic samples and small biopsies for not only diagnostic purposes but also for ancillary testing. In some instances, the ancillary tests contribute to the diagnosis and in other scenarios, they provide prognostic and theranostic information for the management of patients with advanced stage cancer. These ancillary tests include immunohistochemical biomarker analysis, molecular mutation analysis, and cytogenetic tests. Despite the finite nature of the cellular material procured in cytologic and small tissue biopsies, pathologists are tasked with ordering an increasing number of tests using these limited samples. This requires the pathologists to utilize and triage these samples in an optimal fashion so that as much information can be gleaned from a given specimen. This review will focus on the pre-analytic requirements for ancillary molecular and cytogenetic tests in the context of a discussion of the various preparation methods for cytologic and small biopsy specimens. The goal will be to provide the reader with the necessary concepts that can be utilized to develop optimal specimen selection and triage strategies to maximize the chances of effectively utilizing these samples for comprehensive diagnostic and relevant ancillary testing purposes.
Indexed as
Identifiers
30600323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.